Cell fusion: From hybridoma to dendritic cell-based vaccine

Expert Review of Vaccines

Volumn 7, Issue 7, 2008, Pages 1055-1068

  Gong, Jianlin ^a   Koido, Shigeo ^b   Calderwood, Stuart K ^c  

^a BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b JIKEI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Cancer immunotherapy; CD4+ T cell; CD8+ T cell; Dendritic cell; Tumor vaccine; Tumor dendritic cell fusion

Indexed keywords

AUTOANTIGEN; AUTOLOGOUS DENDRITIC CELL TUMOR FUSION VACCINE; B16 DC GM FUSION VACCINE; CPG OLIGODEOXYNUCLEOTIDE; CYTOKINE EXPRESSING FUSION VACCINE; DC GLIOMA FUSION VACCINE; DENDRITIC CELL VACCINE; FC MUC1 VACCINE; FUSION CELL VACCINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 12; INTERLEUKIN 18; MEMBRANE PROTEIN; MUCIN 1; PEG GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR FUSION VACCINE; PICIBANIL; TOLL LIKE RECEPTOR 9; TOLL LIKE RECEPTOR AGONIST; TUMOR ANTIGEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; VESICULAR STOMATITIS VIRUS FUSOGENIC MEMBRANE GLYCOPROTEIN; VIRAL FUSOGENIC MEMBRANE GLYCOPROTEIN;

ANIMAL CELL; ANTIGEN PRESENTATION; ANTINEOPLASTIC ACTIVITY; CANCER IMMUNOTHERAPY; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL FUSION; ELECTROFUSION (CELL); GENE FUSION; HAIR DISCOLORATION; HUMAN; HUMAN CELL; HYBRIDOMA; IMMUNE RESPONSE; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; KIDNEY CARCINOMA; LUNG METASTASIS; NONHUMAN; PRIORITY JOURNAL; QUALITY CONTROL; REVIEW; VESICULAR STOMATITIS VIRUS; VIRUS MEDIATED FUSION;

ANIMALS; CANCER VACCINES; CELL FUSION; DENDRITIC CELLS; HUMANS; IMMUNOTHERAPY; NEOPLASMS;

EID: 51349099842     PISSN: 14760584     EISSN: 17448395     Source Type: Journal    
DOI: 10.1586/14760584.7.7.1055     Document Type: Review

References (162)

1. Pardoll D. Does the immune system see tumors as foreign or self? Annu. Rev. Immunol. 21, 807-839 (2003). •• Outstanding review of the immune system and how to regulate tumor immunity or tolerance induction.
2. Rosenberg SA. Shedding light on tumor immunotherapy of cancer. N. Engl. J. Med. 350, 1461-1463 (2004).
3. Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines. Nature Med. 10, 909-915 (2004).
4. Finn OJ. Cancer vaccines: between the idea and the reality. Nat. Rev. Immunol. 3(8), 630-641 (2003). •• Very thorough analysis of the challenges facing cancer vaccines.
5. Primakoff P, Myles DG. Penetration, adhesion, and fusion in mammalian sperm-egg interaction. Science 296(5576), 2183-2185 (2002).
6. Chen EH, Olson EN. Towards a molecular pathway for myoblast fusion in Drosophila. Trends Cell Biol. 14(8), 452-460 (2004).
7. Stolzing A, Hescheler J, Sethe S. Fusion and regenerative therapies: is immortality really recessive? Rejuvenation Res. 10(4), 571-586 (2007).
8. Guccion JG, Enzinger FM. Malignant giant cell tumor of soft parts. An analysis of 32 cases. Cancer 29(6), 1518-1529 (1972).
9. Okada Y, Tadokoro J. The distribution of cell fusion capacity among several cell strains or cells caused by HVJ. Exp. Cell Res. 32, 417-430 (1963).
10. Okada Y, Yamada K, Tadokoro J. Effect of antiserum on the cell fusion reaction caused by HVJ. Virology 22, 397-409 (1964).
11. Okada Y, Kim J, Maeda Y, Koseki I. Specific movement of cell membranes fused with HVJ (Sendai virus). Proc. Natl Acad. Sci. USA 71(5), 2043-2047 (1974).
12. Furusawa M, Nishimura T, Yamaizumi M, Okada Y. Injection of foreign substances into single cells by cell fusion. Nature 249(456), 449-450 (1974).
13. Frye LD, Edidin M. The rapid intermixing of cell surface antigens after formation of mouse-human heterokaryons. J. Cell Sci. 7(2), 319-335 (1970).
14. Singer SJ, Nicolson GL. The fluid mosaic model of the structure of cell membranes. Science 175(23), 720-731 (1972).
15. Rodriguez-Tome P, Lijnzaad P. The radiation hybrid database. Nucleic Acids Res. 27(1), 115-118 (1999).
16. Islam MQ, Meirelles Lda S, Nardi NB, Magnusson P, Islam K. Polyethylene glycol-mediated fusion between primary mouse mesenchymal stem cells and mouse fibroblasts generates hybrid cells with increased proliferation and altered differentiation. Stem Cells Dev. 15(6), 905-919 (2006).
17. Kohler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256(5517), 495-497 (1975). •• Landmark discovery that has revolutionized the production of antibodies.
18. Galfre G, Howe SC, Milstein C, Butcher GW, Howard JC. Antibodies to major histocompatibility antigens produced by hybrid cell lines. Nature 266(5602), 550-552 (1977).
19. Margulies DH. Monoclonal antibodies: producing magic bullets by somatic cell hybridization. J. Immunol. 174(5), 2451-2452 (2005).
20. Milstein C. The hybridoma revolution: an offshoot of basic research. Bioessays 21(11), 966-973 (1999).
21. Davidson RL, Gerald PS. Improved techniques for the induction of mammalian cell hybridization by polyethylene glycol. Somatic Cell Genet. 2(2), 165-176 (1976).
22. Kuby J. Hybridoma and monoclonal antibody. In: Immunology (Volume 7). Kuby J (Ed.). WH Freeman and Company, NY, USA 141-156 (1992).
23. Steinman RM. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296 (1991). •• Very thorough review of the phenotype and function of dendritic cells (DCs).
24. Steinman RM. Dendritic cells and the control of immunity: enhancing the efficiency of antigen presentation. Mt Sinai. J. Med. 68(3), 106-166 (2001).
25. + T lymphocytes by human blood dendritic cells in vitro. J. Clin. Invest. 90(1), 229-237 (1992).
26. Inaba K, Witmer-Pack M, Inaba M et al. The tissue distribution of the B7-2 costimulator in mice: abundant expression on dendritic cells in situ and during maturation in vitro. J. Exp. Med. 180(5), 1849-1860 (1994).
27. Young JW, Inaba K. Dendritic cells as adjuvants for class I major histocompatibility complex-restricted antitumor immunity. J. Exp. Med. 183(1), 7-11 (1996).
28. Inaba K, Pack M, Inaba M et al. High levels of a major histocompatibility complex II-self peptide complex on dendritic cells from the T cell areas of lymph nodes. J. Exp. Med. 186(5), 665-672 (1997).
29. Thery C, Amigorena S. The cell biology of antigen presentation in dendritic cells. Curr. Opin. Immunol. 13(1), 45-51 (2001).
30. Celluzzi CM, Mayordomo JI, Storkus WJ, Lotze MT, Falo LD Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183(1), 283-287 (1996).
31. Mayordomo JI, Zorina T, Storkus WJ et al. Bone marrow-derived dendritic cells pulsed with synthetic tumour peptides elicit protective and therapeutic antitumour immunity. Nat. Med. 1(12), 1297-1302 (1995).
32. Paglia P, Chiodoni C, Rodolfo M, Colombo MP. Murine dendritic cells loaded in vitro with soluble protein prime cytotoxic T lymphocytes against tumor antigen in vivo. J. Exp. Med. 183(1), 317-322 (1996).
33. Nestle FO, Alijagic S, Gilliet M et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat. Med. 4(3), 328-332 (1998).
34. Hsu FJ, Benike C, Fagnoni F et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat. Med. 2(1), 52-58 (1996).
35. Loveland BE, Zhao A, White S et al. Mannan-MUC1-pulsed dendritic cell immunotherapy: a Phase I trial in patients with adenocarcinoma. Clin. Cancer Res. 12(3 Pt 1), 869-877 (2006).
36. Gong J, Chen L, Chen D et al. Induction of antigen-specific antitumor immunity with adenovirus-transduced dendritic cells. Gene Ther. 4(10), 1023-1028 (1997).
37. Tang CK, Lodding J, Minigo G et al. Mannan-mediated gene delivery for cancer immunotherapy. Immunology 120(3), 325-335 (2007).
38. Koido S, Kashiwaba M, Chen D et al. Induction of antitumor immunity by vaccination of dendritic cells transfected with MUC1 RNA. J. Immunol. 165(10), 5713-5719 (2000).
39. Specht JM, Wang G, Do MT et al. Dendritic cells retrovirally transduced with a model antigen gene are therapeutically effective against established pulmonary metastases. J. Exp. Med. 186(8), 1213-1221 (1997).
40. Condon C, Watkins SC, Celluzzi CM, Thompson K, Falo LD Jr. DNA-based immunization by in vivo transfection of dendritic cells. Nat. Med. 2(10), 1122-1128 (1996).
41. Gong J, Chen D, Kashiwaba M, Kufe D. Induction of antitumor activity by immunization with fusions of dendritic and carcinoma cells. Nat. Med. 3(5), 558-561 (1997). • First publication that provides proof of principle for DC/tumor fusion vaccine.
42. Gong J, Koido S, Chen D et al. Immunization against murine multiple myeloma with fusions of dendritic and plasmacytoma cells is potentiated by interleukin 12. Blood 99(7), 2512-2517 (2002).
43. Liu Y, Zhang W, Chan T, Saxena A, Xiang J. Engineered fusion hybrid vaccine of IL-4 gene-modified myeloma and relative mature dendritic cells enhances antitumor immunity. Leuk. Res. 26(8), 757-763 (2002).
44. Lindner M, Schirrmacher V. Tumour cell-dendritic cell fusion for cancer immunotherapy: comparison of therapeutic efficiency of polyethylen-glycol versus electro-fusion protocols. Eur. J. Clin. Invest. 32(3), 207-217 (2002).
45. Homma S, Toda G, Gong J, Kufe D, Ohno T. Preventive antitumor activity against hepatocellular carcinoma (HCC) induced by immunization with fusions of dendritic cells and HCC cells in mice. J. Gastroenterol. 36(11), 764-771 (2001).
46. Cao X, Zhang W, Wang J et al. Therapy of established tumour with a hybrid cellular vaccine generated by using granulocyte-macrophage colony-stimulating factor genetically modified dendritic cells. Immunology 97(4), 616-625 (1999).
47. Wang J, Saffold S, Cao X, Krauss J, Chen W. Eliciting T cell immunity against poorly immunogenic tumors by immunization with dendritic cell-tumor fusion vaccines. J. Immunol. 161(10), 5516-5524 (1998). • Reports that tumor antigens are processed through the endogenous pathway of DC after fusion and that T cells primed by tumor cell vaccine are high-quality tumor-reactive cells, capable of mediating regression of disseminated FBL-3 tumor.
48. Hayashi T, Tanaka H, Tanaka J et al. Immunogenicity and therapeutic efficacy of dendritic-tumor hybrid cells generated by electrofusion. Clin. Immunol. 104(1), 14-20 (2002).
49. Xia J, Tanaka Y, Koido S et al. Prevention of spontaneous breast carcinoma by prophylactic vaccination with dendritic/tumor fusion cells. J. Immunol. 170(4), 1980-1986 (2003).
50. Kao JY, Gong Y, Chen CM, Zheng QD, Chen JJ. Tumor-derived TGF-b reduces the efficacy of dendritic cell/tumor fusion vaccine. J. Immunol. 170(7), 3806-3811 (2003).
51. Takeda A, Homma S, Okamoto T, Kufe D, Ohno T. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity. Eur. J. Clin. Invest. 33(10), 897-904 (2003).
52. Zhang JK, Li J, Zhang J, Chen HB, Chen SB. Antitumor immunopreventive and immunotherapeutic effect in mice induced by hybrid vaccine of dendritic cells and hepatocarcinoma in vivo. World J. Gastroenterol. 9(3), 479-484 (2003).
53. Li J, Holmes LM, Franek KJ et al. Purified hybrid cells from dendritic cell and tumor cell fusions are superior activators of antitumor immunity. Cancer Immunol. Immunother. 50(9), 456-462 (2001).
54. Xia D, Chan T, Xiang J. Dendritic cell/myeloma hybrid vaccine. Methods Mol. Med. 113, 225-233 (2005).
55. Homma S, Kikuchi T, Ishiji N et al. Cancer immunotherapy by fusions of dendritic and tumour cells and rh-IL-12. Eur. J. Clin. Invest. 35(4), 279-286 (2005).
56. Kao JY, Zhang M, Chen CM, Chen JJ. Superior efficacy of dendritic cell-tumor fusion vaccine compared with tumor lysate-pulsed dendritic cell vaccine in colon cancer. Immunol. Lett. 101(2), 154-159 (2005).
57. Ogawa F, Iinuma H, Okinaga K. Dendritic cell vaccine therapy by immunization with fusion cells of interleukin-2 gene-transduced, spleen-derived dendritic cells and tumour cells. Scand. J. Immunol. 59(5), 432-439 (2004).
58. Akasaki Y, Kikuchi T, Homma S et al. Antitumor effect of immunizations with fusions of dendritic and glioma cells in a mouse brain tumor model. J. Immunother. 24(2), 106-113 (2001).
59. Scott-Taylor TH, Pettengell R, Clarke I et al. Human tumour and dendritic cell hybrids generated by electrofusion: potential for cancer vaccines. Biochim. Biophys. Acta 1500(3), 265-279 (2000). • Analyzes the factors that influence the fusion efficiency and/or cell viability through electrofusion.
60. Tanaka H, Shimizu K, Hayashi T, Shu S. Therapeutic immune response induced by electrofusion of dendritic and tumor cells. Cell. Immunol. 220(1), 1-12 (2002).
61. Siders WM, Vergilis KL, Johnson C, Shields J, Kaplan JM. Induction of specific antitumor immunity in the mouse with the electrofusion product of tumor cells and dendritic cells. Mol. Ther. 7(4), 498-505 (2003).
62. Jantscheff P, Spagnoli G, Zajac P, Rochlitz CF. Cell fusion: an approach to generating constitutively proliferating human tumor antigen-presenting cells. Cancer Immunol. Immunother. 51(7), 367-375 (2002).
63. Goddard RV, Prentice AG, Copplestone JA, Kaminski ER. In vitro dendritic cell-induced T cell responses to B cell chronic lymphocytic leukaemia enhanced by IL-15 and dendritic cell-B-CLL electrofusion hybrids. Clin. Exp. Immunol. 131(1), 82-89 (2003).
64. Marten A, Renoth S, Heinicke T et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical Phase I/II trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 14(5), 483-494 (2003).
65. Trevor KT, Cover C, Ruiz YW et al. Generation of dendritic cell-tumor cell hybrids by electrofusion for clinical vaccine application. Cancer Immunol. Immunother. 53(8), 705-714 (2004).
66. Suzuki T, Fukuhara T, Tanaka M et al. Vaccination of dendritic cells loaded with interleukin-12-secreting cancer cells augments in vivo antitumor immunity: characteristics of syngeneic and allogeneic antigen-presenting cell cancer hybrid cells. Clin. Cancer Res. 11(1), 58-66 (2005).
67. Trefzer U, Herberth G, Wohlan K et al. Tumour-dendritic hybrid cell vaccination for the treatment of patients with malignant melanoma: immunological effects and clinical results. Vaccine 23(17-18), 2367-2373 (2005). • Reports immunological and clinical response to the vaccination of patient-derived melanoma cells fused to allogeneic DCs in 17 patients with advanced melanoma: one complete response, one partial response and six cases of stable disease.
68. Shimizu K, Kuriyama H, Kjaergaard J et al. Comparative analysis of antigen loading strategies of dendritic cells for tumor immunotherapy. J. Immunother. 27(4), 265-272 (2004). • Reports that fusions of DCs and tumor cells are far superior to other methods of DC loading.
69. Phan V, Errington F, Cheong SC et al. A new genetic method to generate and isolate small, short-lived but highly potent dendritic cell-tumor cell hybrid vaccines. Nat. Med. 9(9), 1215-1219 (2003). • Provides evidence that fusion cells function as antigen-presenting cells and demonstrates a new approach to rapidly select fusion cells.
70. Hiraoka K, Yamamoto S, Otsuru S et al. Enhanced tumor-specific long-term immunity of hemagglutinating [correction of hemaggluttinating] virus of Japan-mediated dendritic cell-tumor fused cell vaccination by coadministration with CpG oligodeoxynucleotides. J. Immunol. 173(7), 4297-4307 (2004).
71. Steinman RM, Swanson J. The endocytic activity of dendritic cells. J. Exp. Med. 182(2), 283-288 (1995).
72. Watts C. The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat. Immunol. 5(7), 685-692 (2004).
73. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu. Rev. Immunol. 19, 47-64 (2001).
74. Berard F, Blanco P, Davoust J et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. 192(11), 1535-1544 (2000).
75. Wolkers MC, Brouwenstijn N, Bakker AH, Toebes M, Schumacher TN. Antigen bias in T cell cross-priming. Science 304(5675), 1314-1317 (2004).
76. Koido S, Ohana M, Liu C et al. Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation. Clin. Immunol. 113(3), 261-269 (2004).
77. Galea-Lauri J, Darling D, Mufti G, Harrison P, Farzaneh F. Eliciting cytotoxic T lymphocytes against acute myeloid leukemia-derived antigens: evaluation of dendritic cell-leukemia cell hybrids and other antigen-loading strategies for dendritic cell-based vaccination. Cancer Immunol. Immunother. 51(6), 299-310 (2002).
78. Gong J, Chen D, Kashiwaba M et al. Reversal of tolerance to human MUC1 antigen in MUC1 transgenic mice immunized with fusions of dendritic and carcinoma cells. Proc. Natl Acad. Sci. USA 95(11), 6279-6283 (1998).
79. Lespagnard L, Mettens P, Verheyden AM et al. Dendritic cells fused with mastocytoma cells elicit therapeutic antitumor immunity. Int. J. Cancer. 76(2), 250-258 (1998).
80. Koido S, Hara E, Homma S et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res. 11(21), 7891-7900 (2005).
81. Koido S, Tanaka Y, Chen D, Kufe D, Gong J. The kinetics of in vivo priming of CD4 and CD8 T cells by dendritic/tumor fusion cells in MUC1-transgenic mice. J. Immunol. 168(5), 2111-2117 (2002).
82. Ratta M, Fagnoni F, Curti A et al. Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6. Blood 100(1), 230-237 (2002).
83. Satthaporn S, Robins A, Vassanasiri W et al. Dendritic cells are dysfunctional in patients with operable breast cancer. Cancer Immunol. Immunother. 53(6), 510-518 (2004).
84. Orsini E, Guarini A, Chiaretti S, Mauro FR, Foa R. The circulating dendritic cell compartment in patients with chronic lymphocytic leukemia is severely defective and unable to stimulate an effective T-cell response. Cancer Res. 63(15), 4497-4506 (2003).
85. + T-cell response. Nat. Rev. Immunol. 4(8), 595-602 (2004). •• Very thorough review of different requirements for the induction of cellular immunity against antigen from microbes or cellular antigen and the role of CD4 T cells in the generation of sustainable cytotoxic T lymphocytes.
86. Parkhurst MR, DePan C, Riley JP, Rosenberg SA, Shu S. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. J. Immunol. 170(10), 5317-5325 (2003).
87. Galea-Lauri J, Wells JW, Darling D, Harrison P, Farzaneh F. Strategies for antigen choice and priming of dendritic cells influence the polarization and efficacy of antitumor T-cell responses in dendritic cell-based cancer vaccination. Cancer Immunol. Immunother. 53(11), 963-977 (2004).
88. Kokhaei P, Rezvany MR, Virving L et al. Dendritic cells loaded with apoptotic tumour cells induce a stronger T-cell response than dendritic cell-tumour hybrids in B-CLL. Leukemia 17(5), 894-899 (2003).
89. Dranoff G, Jaffee E, Lazenby A et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent, specific, and long-lasting anti-tumor immunity. Proc. Natl Acad. Sci. USA 90(8), 3539-3543 (1993).
90. + T cells in the antitumor immune response. J. Exp. Med. 188(12), 2357-2368 (1998).
91. Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J. Exp. Med. 187(5), 693-702 (1998).
92. + T cells have a major 'post-licensing' role in CTL mediated anti-tumor immunity. J. Immunol. 165(11), 6047-6055 (2000).
93. Marzo AL, Lake RA, Robinson BW, Scott B. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors. Cancer Res. 59(5), 1071-1079 (1999).
94. Greenberg PD. Adoptive T cell therapy of tumors: mechanisms operative in the recognition and elimination of tumor cells. Adv. Immunol. 49, 281-355 (1991).
95. + T lymphocytes. J. Exp. Med. 189(5), 767-778 (1999).
96. +) T cells eliminate MHC class II-negative cancer cells in vivo by indirect effects of IFN-γ. Proc. Natl Acad. Sci. USA 96(15), 8633-8638 (1999).
97. + T cell-mediated tumor rejection involves inhibition of angiogenesis that is dependent on IFN γ receptor expression by nonhematopoietic cells. Immunity 12(6), 677-686 (2000).
98. + T-helper and a T-killer cell. Nature 393(6684), 474-478 (1998).
99. Mitchison NA. An exact comparison between the efficiency of two- and three-cell-type clusters in mediating helper activity. Eur. J. Immunol. 20(3), 699-702 (1990).
100. + T cell help. J. Exp. Med. 186(1), 65-70 (1997).
101. Behrens G, Li M, Smith CM et al. Helper T cells, dendritic cells and CTL immunity. Immunol. Cell Biol. 82(1), 84-90 (2004).
102. Celluzzi CM, Falo LD, Jr. Physical interaction between dendritic cells and tumor cells results in an immunogen that induces protective and therapeutic tumor rejection. J. Immunol. 160(7), 3081-3085 (1998).
103. Kjaergaard J, Shimizu K, Shu S. Electrofusion of syngeneic dendritic cells and tumor generates potent therapeutic vaccine. Cell. Immunol. 225(2), 65-74 (2003).
104. + T cells from MUC1 transgenic mice immunized with dendritic-carcinoma fusion cells. Immunology 101(3), 316-324 (2000).
105. Krause SW, Neumann C, Soruri A et al. The treatment of patients with disseminated malignant melanoma by vaccination with autologous cell hybrids of tumor cells and dendritic cells. J. Immunother. 25(5), 421-428 (2002).
106. Kikuchi T, Akasaki Y, Irie M et al. Results of a Phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells. Cancer Immunol. Immunother. 50(7), 337-344 (2001). • Reports the results of the first clinical trial of fusion cell vaccine in patients with glioma. The vaccine is safe and partial response was observed in two patients out of six cases analyzed.
107. Avigan D, Vasir B, Gong J et al. Fusion cell vaccination of patients with metastatic breast and renal cancer induces immunological and clinical responses. Clin. Cancer Res. 10(14), 4699-4708 (2004).
108. Avigan DE, Vasir B, George DJ et al. Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J. Immunother. 30(7), 749-761 (2007).
109. Haenssle HA, Krause SW, Emmert S et al. Hybrid cell vaccination in metastatic melanoma: clinical and immunologic results of a Phase I/II study. J. Immunother. 27(2), 147-155 (2004).
110. Zou W. Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat. Rev. Cancer 5(4), 263-274 (2005).
111. Schnare M, Barton GM, Holt AC et al. Toll-like receptors control activation of adaptive immune responses. Nat. Immunol. 2(10), 947-950 (2001).
112. Michelsen KS, Aicher A, Mohaupt M et al. The role of Toll-like receptors (TLRs) in bacteria-induced maturation of murine dendritic cells (DCS). Peptidoglycan and lipoteichoic acid are inducers of DC maturation and require TLR2. J. Biol. Chem. 276(28), 25680-25686 (2001).
113. Kaisho T, Akira S. Dendritic-cell function in Toll-like receptor- and MyD88-knockout mice. Trends Immunol. 22(2), 78-83 (2001).
114. Xia D, Li F, Xiang J. Engineered fusion hybrid vaccine of IL-18 gene-modified tumor cells and dendritic cells induces enhanced antitumor immunity. Cancer Biother. Radiopharm. 19(3), 322-330 (2004).
115. Vasir B, Wu Z, Crawford K et al. Fusions of dendritic cells with breast carcinoma stimulate the expansion of regulatory T cells while concomitant exposure to IL-12, CpG oligodeoxynucleotides, and anti-CD3/CD28 promotes the expansion of activated tumor reactive cells. J. Immunol. 181(1), 808-821 (2008).
116. + regulatory T cells. Clin. Cancer Res. 14(8), 2413-2420 (2008).
117. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6(4), 295-307 (2006).
118. Menard C, Martin F, Apetoh L, Bouyer F, Ghiringhelli F. Cancer chemotherapy: not only a direct cytotoxic effect, but also an adjuvant for antitumor immunity. Cancer Immunol. Immunother. (2008) [Epub ahead of print] DOI: 10.1007/s00262-008-0505-6.
119. Iinuma T, Homma S, Noda T et al. Prevention of gastrointestinal tumors based on adenomatous polyposis coli gene mutation by dendritic cell vaccine. J. Clin. Invest. 113(9), 1307-1317 (2004).
120. Coughlin CM, Wysocka M, Kurzawa HL et al. B7-1 and interleukin 12 synergistically induce effective antitumor immunity. Cancer Res. 55(21), 4980-4987 (1995).
121. Mountford AP, Anderson S, Wilson RA. Induction of Th1 cell-mediated protective immunity to Schistosoma mansoni by co-administration of larval antigens and IL-12 as an adjuvant. J. Immunol. 156(12), 4739-4745 (1996).
122. Grohmann U, Bianchi R, Ayroldi E et al. A tumor-associated and self antigen peptide presented by dendritic cells may induce T cell anergy in vivo, but IL-12 can prevent or revert the anergic state. J. Immunol. 158(8), 3593-3602 (1997).
123. Okamoto M, Furuichi S, Nishioka Y et al. Expression of Toll-like receptor 4 on dendritic cells is significant for anticancer effect of dendritic cell-based immunotherapy in combination with an active component of OK-432, a streptococcal preparation. Cancer Res. 64(15), 5461-5470 (2004).
124. Heckelsmiller K, Beck S, Rall K et al. Combined dendritic cell- and CpG oligonucleotide-based immune therapy cures large murine tumors that resist chemotherapy. Eur. J. Immunol. 32(11), 3235-3245 (2002).
125. Nakahara S, Tsunoda T, Baba T, Asabe S, Tahara H. Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. Cancer Res. 63(14), 4112-4118 (2003).
126. Yamanaka R, Homma J, Yajima N et al. Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical Phase I/II trial. Clin. Cancer Res. 11(11), 4160-4167 (2005).
127. Koido S, Hara E, Homma S et al. Streptococcal preparation OK-432 promotes fusion efficiency and enhances induction of antigen-specific CTL by fusions of dendritic cells and colorectal cancer cells. J. Immunol. 178(1), 613-622 (2007).
128. Koido S, Hara E, Homma S et al. Synergistic induction of antigen-specific CTL by fusions of TLR-stimulated dendritic cells and heat-stressed tumor cells. J. Immunol. 179(7), 4874-4883 (2007).
129. Du YC, Lin P, Zhang J et al. Fusion of CpG-ODN-stimulating dendritic cells with Lewis lung cancer cells can enhance anti-tumor immune responses. Tissue Antigens 67(5), 368-376 (2006).
130. Gong J, Nikrui N, Chen D et al. Fusions of human ovarian carcinoma cells with autologous or allogeneic dendritic cells induce antitumor immunity. J. Immunol. 165(3), 1705-1711 (2000).
131. Gong J, Avigan D, Chen D et al. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl Acad. Sci. USA 97(6), 2715-2718 (2000).
132. Raje N, Hideshima T, Davies FE et al. Tumour cell/dendritic cell fusions as a vaccination strategy for multiple myeloma. Br. J. Haematol. 25(3), 343-352 (2004).
133. Gong J, Koido S, Kato Y et al. Induction of anti-leukemic cytotoxic T lymphocytes by fusion of patient-derived dendritic cells with autologous myeloblasts. Leuk. Res. 28(12), 1303-1312 (2004).
134. + CTL in MHC class I-deficient mice through CD4 to CD8 conversion. J. Immunol. 172(12), 7848-7858 (2004).
135. Tamai H, Watanabe S, Zheng R et al. Effective treatment of spontaneous metastases derived from a poorly immunogenic murine mammary carcinoma by combined dendritic-tumor hybrid vaccination and adoptive transfer of sensitized T cells. Clin. Immunol. 127(1), 66-77 (2008). • Provides proof of principle for combined active and adoptive immunotherapy in the treatment of cancer.
136. Homma S, Matai K, Irie M et al. Immunotherapy using fusions of autologous dendritic cells and tumor cells showed effective clinical response in a patient with advanced gastric carcinoma. J. Gastroenterol. 38(10), 989-994 (2003).
137. Koido S, Hara E, Torii A et al. Induction of antigen-specific CD4- and CD8-mediated T-cell responses by fusions of autologous dendritic cells and metastatic colorectal cancer cells. Int. J. Cancer 117(4), 587-595 (2005).
138. Gottfried E, Krieg R, Eichelberg C et al. Characterization of cells prepared by dendritic cell-tumor cell fusion. Cancer Immun. 2, 15 (2002).
139. Bischoff R, Eisert RM, Schedel I, Vienken J, Zimmerman U. Human hybridoma cells produced by electrofusion. FEBS Lett. 147(1), 64-68 (1982).
140. Gabrijel M, Repnik U, Kreft M et al. Quantification of cell hybridoma yields with confocal microscopy and flow cytometry. Biochem. Biophys. Res. Commun. 314(3), 717-723 (2004).
141. Neil GA, Zimmermann U. Electrofusion. Methods Enzymol. 220, 174-196 (1993).
142. Kinzler ER, Compton T. Characterization of human cytomegalovirus glycoprotein-induced cell-cell fusion. J. Virol. 79(12), 7827-7837 (2005).
143. Plattet P, Rivals JP, Zuber B et al. The fusion protein of wild-type canine distemper virus is a major determinant of persistent infection. Virology 337(2), 312-326 (2005).
144. Negrete OA, Levroney EL, Aguilar HC et al. EphrinB2 is the entry receptor for Nipah virus, an emergent deadly paramyxovirus. Nature 436(7049), 401-405 (2005).
145. Lamb RA, Kolakofsky D. Paramyxoviridae: the viruses and their replication. Fields Virology 4th 1305-1340 (2001).
146. Pare ME, Gauthier S, Landry S et al. A new sensitive and quantitative HTLV-I-mediated cell fusion assay in T cells. Virology 338(2), 309-322 (2005).
147. Bateman A, Bullough F, Murphy S et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res. 60(6), 1492-1497 (2000).
148. Linardakis E, Bateman A, Phan V et al. Enhancing the efficacy of a weak allogeneic melanoma vaccine by viral fusogenic membrane glycoprotein-mediated tumor cell-tumor cell fusion. Cancer Res. 62(19), 5495-5504 (2002).
149. Ebert O, Shinozaki K, Kournioti C et al. Syncytia induction enhances the oncolytic potential of vesicular stomatitis virus in virotherapy for cancer. Cancer Res. 64(9), 3265-3270 (2004).
150. Bateman AR, Harrington KJ, Kottke T et al. Viral fusogenic membrane glycoproteins kill solid tumor cells by nonapoptotic mechanisms that promote cross presentation of tumor antigens by dendritic cells. Cancer Res. 62(22), 6566-6578 (2002).
151. Holmes LM, Li J, Sticca RP, Wagner TE, Wei Y. A rapid, novel strategy to induce tumor cell-specific cytotoxic T lymphoctye responses using instant dentritomas. J. Immunother. 24(2), 122-129 (2001).
152. Chen D, Xia J, Tanaka Y et al. Immunotherapy of spontaneous mammary carcinoma with fusions of dendritic cells and mucin 1-positive carcinoma cells. Immunology 109(2), 300-307 (2003).
153. Tanaka Y, Koido S, Chen D et al. Vaccination with allogeneic dendritic cells fused to carcinoma cells induces antitumor immunity in MUC1 transgenic mice. Clin. Immunol. 101(2), 192-200 (2001).
154. Walden P. Hybrid cell vaccination for cancer immunotherapy. Adv Exp Med Biol, 465, 347-354 (2000).
155. Fabre JW. The allogeneic response and tumor immunity. Nat. Med. 7(6), 649-652 (2001).
156. Ford WL, Atkins RC. The proportion of lymphocytes capable of recognizing strong transplantation antigens in vivo. Adv. Exp. Med. Biol. 29(0), 255-262 (1973).
157. Ford WL, Simmonds SJ, Atkins RC. Early cellular events in a systemic graft-vs.-host reaction. II. Autoradiographic estimates of the frequency of donor lymphocytes which respond to each Ag-B-determined antigenic complex. J. Exp. Med. 141(3), 681-696 (1975).
158. Sherman LA, Chattopadhyay S. The molecular basis of allorecognition. Annu. Rev. Immunol. 11, 385-402 (1993).
159. Lundqvist A, Palmborg A, Bidla G et al. Allogeneic tumor-dendritic cell fusion vaccines for generation of broad prostate cancer T-cell responses. Med. Oncol. 21(2), 155-165 (2004).
160. Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J. Clin. 50(1), 7-33 (2000).
161. Chomez P, De Backer O, Bertrand M et al. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res. 61(14), 5544-5551 (2001).
162. Koido S, Tanaka Y, Tajiri H, Gong J. Generation and functional assessment of antigen-specific T cells stimulated by fusions of dendritic cells and allogeneic breast cancer cells. Vaccine 25(14), 2610-2619 (2007).